Chabiotech차바이오텍
085660 · KOSDAQ · ₩085660 · 차바이오텍
- Market cap
- ₩654B
- Enterprise value
- ₩511B
- P/E
- 45.8×
- P/B
- 1.6×
- Dividend yield
- 0.0%
- ROE
- 3.4%
- Net margin
- 1.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.6% from the high
₩7,000Today: ₩7,010 – ₩7,340₩23,950
Returns
- 1W−8.2%
- 1M−11.7%
- 3M−16.9%
- 6M−59.9%
- YTD−52.1%
- 1Y−46.9%
- Volume today
- 200,962
- 1.0× the 20-day average
- Traded today
- ₩1.4B
- Listed shares
- 92,972,846
- EPS (12 months)
- ₩154
- Earnings yield 2.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumWeak-10% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩411M at the close (26.2% of 20-day average trading value)
On its 18 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 46.3% of trading value and pointed the same way 15 of 18 times.
- 2× KODEX KOSDAQ150 Leverage −₩347M
- -1× KODEX KOSDAQ150 Futures Inverse −₩29M
- 2× TIGER KOSDAQ150 Leverage −₩26M
- 2× RISE KOSDAQ150 Futures Leverage −₩7.4M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.3%
- KODEX KOSDAQ150 Leverage2×0.3%
- TIGER KOSDAQ1500.3%
- RISE KOSDAQ1500.3%
- TIGER KOSDAQ150 Leverage2×0.3%
- ACE KOSDAQ 1500.3%
- KIWOOM KOSDAQ1500.3%
- SOL KOSDAQ1500.3%
Estimated from the funds' index or underlying stock.
Chabiotech stock overview
Chabiotech (차바이오텍, KRX: 085660) is listed on KOSDAQ, in the Biotech & Pharma sector. The company stores umbilical cord blood and conducts stem cell research and cell therapy development, offering anti-aging services and consulting based on its accumulated know-how. Its shares closed at ₩7,030 on Oct 27, 2026, down 0.99% on the day, giving it a market value of ₩654B.
Key facts
- Market cap
- ₩654B
- Sector
- Biotech & Pharma
- Latest price change
- −0.99%
- As of
- Oct 27, 2026
- Main business
- The company stores umbilical cord blood and conducts stem cell research and cell therapy development, offering anti-aging services and consulting based on its accumulated know-how.
Quick answers about Chabiotech
- What does Chabiotech do?
- The company stores umbilical cord blood and conducts stem cell research and cell therapy development, offering anti-aging services and consulting based on its accumulated know-how. Through major subsidiaries, it also operates in pharmaceuticals, global contract development and manufacturing (CDMO), overseas medical network expansion, and related healthcare services. Medical services account for the largest share of its consolidated revenue.
- What is the market cap of Chabiotech?
- The market capitalisation of Chabiotech was ₩654B at the close on Oct 27, 2026.
- Who are the largest shareholders of Chabiotech?
- According to the latest official filings, the largest reported holders are Cha Gwang-ryeol (25.12%, as of Sep 14, 2026); KH Green (11.02%, as of Jun 23, 2025); Hanwha General Insurance (8.53%, as of Feb 6, 2026).
- When is the next earnings report from Chabiotech?
- Korean companies rarely announce results dates in advance. Based on when Chabiotech filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own Chabiotech?
- Yes. The National Pension Service held 0.31% of Chabiotech shares as of Dec 31, 2025.
Company profile
The company stores umbilical cord blood and conducts stem cell research and cell therapy development, offering anti-aging services and consulting based on its accumulated know-how. Through major subsidiaries, it also operates in pharmaceuticals, global contract development and manufacturing (CDMO), overseas medical network expansion, and related healthcare services. Medical services account for the largest share of its consolidated revenue.
Written by AI from the company's latest annual report.
- Korean name
- 차바이오텍
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 차원태
- Founded
- Nov 2002
- Listed
- Dec 2005
- Listed shares
- 92,972,846
- Fiscal year ends
- Month 12
- Website
- www.chabio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- [Amended] Decision on Provision of Collateral for Third PartiesOct 16, 2026
- [Amended] Decision on Provision of Collateral for Third PartiesSep 30, 2026
- [Amended] Decision on Provision of Collateral for Third PartiesSep 28, 2026
- Adjustment of Conversion Price for Convertible Shares (Redeemable Convertible Preferred Shares)Sep 17, 2026
- Adjustment of Exercise Price of WarrantsSep 16, 2026
Titles in Korean until English translations are added.
Also known as: Chabiotech / 차바이오텍 / 085660 / KRX:085660
Source: KRX statistical information